← boardnext 2026-12next 2027-06
AVLN
Avalyn Pharma Inc.distress 4/10 · elevated risk$28.79+0%today-13% from 52w high
Lead: Progressive Pulmonary Fibrosis · est. market ~$5B (approx, global)
Revenue
pre-revenue
Liquidity
$123M
Runway
1.0 yrs
Shares 1y
—
Price & events
-2.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.2%
1D
+12.1%
1W
-10.9%
1M
—
3M
—
6M
—
1Y
—
2Y
—
5Y
-2.4%
All
Overview
- Market Cap
- $1.28B
- Enterprise Value
- $1.20B
- Volume
- 6.04K
- 52 Week Range
- $25.68 – $32.97
- Total Shares
- 44.33M
- Float Shares
- 29.68M
- Short %
- 4.88%
- % Held by Insiders
- 0.00%
- % Held by Institutions
- 52.72%
- RVOL
- 0.01x
Pipeline stages · 2 programs
AP02
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
AP01
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 3 trials · 3 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-12 Estimated 50% readout ~2027-01-15 | Phase 2 | AP02 | Idiopathic Pulmonary Fibrosis (IPF) | — | recruiting |
| 2027-06 Estimated 50% readout ~2027-07-16 | Phase 2 | AP01 | Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Pulmonary Fibrosis Secondary to Systemic Sclerosis, Pulmonary Fibrosis, Interstitial Lung Disease, Interstitial Lung Disease, Interstitial Lung Disease Due to Connective Tissue Disease (Disorder), Interstitial Lung Disease in Patients With Rheumatoid Arthritis, Interstitial Lung Disease With Progressive Fibrotic Phenotype in Diseases Classified Elsewhere, Hypersensitivity Pneumonitis, Interstitial Lung Disease With Systemic Sclerosis | — | active not recruiting |
| 2031-12-31 Estimated 50% readout ~2032-02-14 | Phase 2 | AP01 | Progressive Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF) | — | recruiting |
Catalyst news & presentations · 3
- second half of 2027Guided 55%readoutPhase 2AP01 · Expected to report topline 12-month clinical results.SEC 8-K
- 2026-08-14Estimated 45%earningsEarningsEarnings releaseyahoo
- 2026-06-17enrollment completesecondaryPhase 2AP01 · Completed target enrollment of 375 patients in the Phase 2b MIST trial.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $59 (+105% upside) · 4 analysts
- 2026-05-26Evercore ISI GroupOutperform
- 2026-05-26GuggenheimBuy
- 2026-05-26Morgan StanleyOverweight
Competitors — Progressive Pulmonary Fibrosis
Recent news
- 2026-07-20Enterprise value to revenue forward of Avalyn Pharma Inc. – NASDAQ:AVLN - TradingView
- 2026-07-20Price to sales forward of Avalyn Pharma Inc. – NASDAQ:AVLN - TradingView
- 2026-07-20Avalyn Pharma Inc (AVLN:UW): Stock Price, Quote and News - BNN Bloomberg
- 2026-07-18Avalyn Pharma Inc. (NASDAQ:AVLN) Receives Average Rating of "Buy" from Analysts - MarketBeat
- 2026-07-17Avalyn Pharma (NASDAQ:AVLN) Shares Up 5.3% - Here's Why - MarketBeat
- 2026-07-16Avalyn Pharma Inc. - common stock (AVLN) Stock Price, News, Quote & History - FinancialContent
- 2026-07-13AVALYN PHARMA INC (AVLN) News Flow - Moomoo
- 2026-07-10Avalyn Pharma (AVLN) Short Interest & Short Float | Updated Jul 2026 - MarketBeat
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.